These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 15512817

  • 1. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors.
    Anagnostopoulos A, Gika D, Hamilos G, Zervas K, Zomas A, Pouli A, Zorzou M, Kastritis E, Anagnostopoulos N, Tassidou A, Anagnostou D, Dimopoulos MA.
    Leuk Lymphoma; 2004 Nov; 45(11):2275-9. PubMed ID: 15512817
    [Abstract] [Full Text] [Related]

  • 2. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D, Katodritou E, Zervas K.
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [Abstract] [Full Text] [Related]

  • 3. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
    Chim CS, Sim J, Tam S, Tse E, Lie AK, Kwong YL.
    Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
    [Abstract] [Full Text] [Related]

  • 4. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B, Boccadoro M.
    Cancer; 2007 Aug 15; 110(4):824-9. PubMed ID: 17594696
    [Abstract] [Full Text] [Related]

  • 5. International staging system for multiple myeloma.
    Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J.
    J Clin Oncol; 2005 May 20; 23(15):3412-20. PubMed ID: 15809451
    [Abstract] [Full Text] [Related]

  • 6. The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia.
    Dimopoulos M, Gika D, Zervas K, Kyrtsonis M, Symeonidis A, Anagnostopoulos A, Bourantas K, Matsouka C, Pangalis G.
    Leuk Lymphoma; 2004 Sep 20; 45(9):1809-13. PubMed ID: 15223640
    [Abstract] [Full Text] [Related]

  • 7. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH, Xu Y, Mai YJ, Wang YF, Zhao YZ, Zou DH, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr 20; 29(4):217-21. PubMed ID: 18843972
    [Abstract] [Full Text] [Related]

  • 8. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.
    Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H.
    Clin Cancer Res; 2002 Nov 20; 8(11):3377-82. PubMed ID: 12429624
    [Abstract] [Full Text] [Related]

  • 9. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
    Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P.
    J Clin Oncol; 2015 Sep 10; 33(26):2863-9. PubMed ID: 26240224
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Expression and clinical significance of beta-catenin in multiple myeloma].
    Li J, Zhang DB, Luo SK, Zhao Y, Huang BH, Gu JL.
    Ai Zheng; 2007 Sep 10; 26(9):1010-4. PubMed ID: 17927863
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.
    Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR.
    Semin Hematol; 2009 Apr 10; 46(2):110-7. PubMed ID: 19389494
    [Abstract] [Full Text] [Related]

  • 16. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
    Bila J, Jelicic J, Dencic Fekete M, Trajkovic G, Sretenovic A, Perunicic Jovanovic M, Antic D, Mihaljevic B.
    Oncol Res Treat; 2017 Apr 10; 40(10):616-620. PubMed ID: 28950269
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function.
    Dimopoulos MA, Kastritis E, Michalis E, Tsatalas C, Michael M, Pouli A, Kartasis Z, Delimpasi S, Gika D, Zomas A, Roussou M, Konstantopoulos K, Parcharidou A, Zervas K, Terpos E, Greek Myeloma Study Group.
    Ann Oncol; 2012 Mar 10; 23(3):722-729. PubMed ID: 21652580
    [Abstract] [Full Text] [Related]

  • 19. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.
    García-Sanz R, González-Porras JR, Hernández JM, Polo-Zarzuela M, Sureda A, Barrenetxea C, Palomera L, López R, Grande-García C, Alegre A, Vargas-Pabón M, Gutiérrez ON, Rodríguez JA, San Miguel JF.
    Leukemia; 2004 Apr 10; 18(4):856-63. PubMed ID: 14973508
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.